Skip to main content
Physician-scientists at IU School of Medicine conduct ground-breaking liver research to understand primary biliary cholangitis (PBC).

Primary Biliary Cholangitis

Primary biliary cholangitis (PBC), previously called primary biliary cirrhosis, is a chronic disease in which the bile ducts in the liver are slowly destroyed.

Investigators

Open Research Studies for Primary Biliary Cholangitis

Zydus PBC

Enrolling: Yes

Principle Investigator: Raj Vuppalanchi, MD

Duration: 26 weeks

Patient Population: Non-cirrhotic

Drug(s): Oral Saroglitazar

Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis

Enrolling: Yes

Principle Investigator: Raj Vuppalanchi, MD

Duration: 59 weeks

Patient Population: Patients diagnosed with PBC

Drug(s): Saroglitazar Magnesium

Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu

View the study on clinicaltrials.gov

Closed Primary Biliary Cholangitis Studies

  • Intercept 302 - PBC
    Enrolling: No

    Principle Investigator: Raj Vuppalanchi, MD

    Duration: Upwards 6 - 8 years.

    Patient Population: PBC with total Bili > ULN and ≤3x ULN or ALP >5x ULN

    Drug(s): Obeticholic Acid tablet or placebo

  • PBC Itch

    Enrolling: No

    Principle Investigator: Craig Lammert, MD

    Duration: 1 visit

    Patient Population: PBC/Pre-Transplant and history of no/minimal itch or severe itch.

  • Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients with Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

    Enrolling: No

    Principle Investigator: Raj Vuppalanchi, MD

    Duration: 21 weeks

    Patient Population: Patients with moderate to severe itching.

    Drug(s): Oral CR845

    Clinicaltrials.gov